SCHEMBL7010209

SCHEMBL7010209

Cn1cc(-c2c[nH]c(=O)n2-c2cn(C(=O)OCC(Cl)(Cl)Cl)c3ccccc23)c2ccccc21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 3/20 0.37
CAMK2D Q13557 1/20 0.37
CCNT1 O60563 4/20 0.36
CDK9 P50750 4/20 0.36
CCNE2 O96020 3/20 0.36
CDK4 P11802 3/20 0.36
CCND1 P24385 3/20 0.36
CCNE1 P24864 3/20 0.36
CDK2 P24941 3/20 0.36
GSK3B P49841 4/20 0.35
GSK3A P49840 2/20 0.35
MEN1 O00255 1/20 0.35
CASK O14936 1/20 0.35
RPS6KA5 O75582 1/20 0.35
CCNK O75909 1/20 0.35
STK10 O94804 1/20 0.35
PRKD3 O94806 1/20 0.35
TP53 P04637 1/20 0.35
PRKCG P05129 1/20 0.35
PRKCB P05771 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7008865 0.90 PIM1 (0.40) PIM1CAMK2DCCNT1CDK9CCNE2
SCHEMBL6977867 0.82 ATM (0.35) PIM1CAMK2DCCNT1CDK9CCNE2
SCHEMBL7013228 0.81 PIM1 (0.42) PIM1CCNT1CDK9CCNE2CDK4
SCHEMBL7008320 0.76 RPS6KB1 (0.41) PIM1CAMK2DCCNT1CDK9CCNE2
SCHEMBL7009411 0.76 ALDH1A1 (0.41) PIM1CAMK2DCCNT1CDK9CDK4
SCHEMBL7007161 0.75 CAMK2D (0.57) PIM1CAMK2DCCNT1CDK9PRKCA
Trifluoroacetic Acid SCHEMBL7007891 0.74 CAMK2D (0.49) PIM1CAMK2DCCNT1CDK9CDK2
SCHEMBL6983870 0.74 L3MBTL1 (0.36) PIM1CCNT1CDK9GSK3BMEN1
SCHEMBL7005539 0.72 CDK4 (0.55) PIM1CAMK2DCCNT1CDK9CCNE2
SCHEMBL7003853 0.71 CAMK2D (0.42) CAMK2DMEN1MAPTKMT2APRKD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030134886-A1 Pharmaceutically active compounds ASTRAZENECA AB, A SWEDISH CORPORATION 2003-07-17 US disclosed
EP-1042317-B1 Indole derivatives as PKC-inhiboitors ASTRAZENECA AB (SE) 2003-05-14 EP disclosed
US-6492409-B1 SUCH AS 5-(1-(3-AMINOPROPYL)-3-INDOLYL)-1-(3-INDOLYL)-1,3-DIHYDROIMIDAZOL-2-ONE; PROTEIN KINASE C INHIBITORS; HIGH SOLUBILITY; REDUCED COLOR; TREATING INFLAMMATORY AND/OR IMMUNOLOGICAL DISORDERS ASTRAZENECA AB (SE) 2002-12-10 US disclosed
US-6337342-B1 ARYLIMIDAZOLONE DERIVATIVES ASTRAZENECA AB (SE) 2002-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030134886-A1 Pharmaceutically active compounds HTR3C, HTR6, CNR1 PIM1 2352/4885CAMK2D 3573/4885CCNT1 354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.